SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + SAD: Pooled Placebo + MD: 30mg WVE-003 + MD: Placebo
Phase 1/2Completed 0 watching 0 views this week💤 Quiet
36
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Huntington Disease
Conditions
Huntington Disease
Trial Timeline
Sep 6, 2021 → May 24, 2024
NCT ID
NCT05032196About SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + SAD: Pooled Placebo + MD: 30mg WVE-003 + MD: Placebo
SAD: 30mg WVE-003 + SAD: 60mg WVE-003 + SAD: 90mg WVE-003 + SAD: Pooled Placebo + MD: 30mg WVE-003 + MD: Placebo is a phase 1/2 stage product being developed by WaVe Life Sciences for Huntington Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT05032196. Target conditions include Huntington Disease.
Hype Score Breakdown
Clinical
13
Activity
8
Company
5
Novelty
4
Community
3
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT05032196 | Phase 1/2 | Completed |
Competing Products
20 competing products in Huntington Disease
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| atomoxetine + Matching Placebo | Eli Lilly | Phase 2 | 52 |
| Votoplam (blinded) + Placebo | Novartis | Phase 3 | 77 |
| Votoplam | Novartis | Phase 2 | 52 |
| Branaplam + Placebo | Novartis | Phase 2 | 52 |
| AFQ056 + Placebo | Novartis | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 1 | 33 |
| Tominersen + Placebo | Roche | Phase 2 | 52 |
| RO7234292 (RG6042) | Roche | Phase 3 | 77 |
| RO7234292 (RG6042) | Roche | Phase 2 | 52 |
| RG6496 + Placebo | Roche | Phase 1 | 33 |
| RO7234292 + Placebo | Roche | Phase 3 | 77 |
| PF-02545920 + PF-02545920 | Pfizer | Phase 2 | 51 |
| Dextromethorphan + Dimebon + Dextromethorphan | Pfizer | Phase 1 | 32 |
| Dimebon | Pfizer | Phase 3 | 76 |
| Dimebon (latrepirdine) | Pfizer | Phase 3 | 76 |
| 20 mg BID of PF-02545920 | Pfizer | Phase 2 | 51 |
| PF-02545920 + Placebo + PF-02545920 + Placebo | Pfizer | Phase 2 | 51 |
| Riluzole | Sanofi | Phase 3 | 76 |
| ALN-HTT02 + Placebo | Alnylam Pharmaceuticals | Phase 1 | 30 |
| Tetrabenazine | Lundbeck | Approved | 82 |